#longeviquest

#longeviquest

"For the ones who are confined in certain spaces or cannot do it independently, this is a great opportunity to transport them to a different reality from the ones that they are currently living in while keeping them active," Munoz told CBC Hamilton from his lab on Laurier's Brantford campus.

Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.

Google's new health tracker, teased by Steph Curry, features a Whoop-inspired design and will include a subscription service with an AI-based personal health coach.

These findings reposition the thymus as a central regulator of immune‑ mediated aging and disease susceptibility in adulthood.

AI tools like RFdiffusion have made protein design dramatically easier, cheaper, and faster. This is accelerating vaccine development, opening new paths for treating genetic diseases, and making science more accessible.

The Israeli gerontologist has been studying healthy centenarians for years and has observed that many follow a pattern similar to Reichert's. They do not always lead a monastic, carefully balanced life. There is a great deal of biological lottery involved in longevity. But Barzilai wants to hack that lottery—to understand which numbers are the winning ones and pass them on to the rest of humanity.

The AI analysis found enormous variation in the health of the thymus between individual people. In some people, it stayed very active until a very old age. And other people, it actually declined very rapidly at a younger age. Importantly, thymus health correlated with a person's overall health. People who had a healthy thymus tended to live longer, have less cancer, and less cardiovascular disease.

Researchers administered one of four doses of stem cells to 118 people between 70 and 85 years old, all of whom had frailty. In a timed walking test nine months after treatment, those who had received the highest dose could walk about 60 metres farther, on average, than they could before treatment.

Even though you're working out hard, you're just not seeing loss of fat and increase in muscle. Based on his own research and experience, TRT can be almost as significant for middle-aged people as eating protein-rich whole foods or moving enough throughout the day, as testosterone starts declining for most people in their 30s, with more notable symptoms appearing around their 40s or 50s.

We are all going to die. No one is happy about that. Today, the internet is full of claims about diets and supplements that will help us live longer. One writer suggested that there are at least 320 longevity clinics operating around the world; some charge $100,000 or more annually for access to their magic elixirs. Unfortunately, the search for a formula that can prevent death, or delay it for a very long time, has a long history of failures.

"As we get older, the immune system is shifting away from good inflammation," which is the body's short-term, acute response to fend off injury or infection and promote healing, explains Dr. Thomas Marron, one of the researchers leading the new study. Marron directs early phase clinical trials at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.